MXCT

MaxCyte Inc
NASDAQHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$112.48M
P/E Ratio
EPS
$-0.37
Beta
1.66
52W High
$2.19
52W Low
$0.64
50-Day MA
$1.18
200-Day MA
$1.17
Dividend Yield
Profit Margin
-121.20%
Forward P/E
PEG Ratio

About MaxCyte Inc

MaxCyte Inc. (MXCT) is a leader in cell-engineering, renowned for its innovative Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins into a variety of cell types. The company serves a prestigious clientele, including top biopharmaceutical firms and research institutions, positioning it favorably within the rapidly expanding cell and gene therapy market. MaxCyte's advanced platforms play a crucial role in the development of novel cell-based therapies and vaccines, responding to the growing global demand for transformative healthcare solutions. With a steadfast commitment to enhancing patient outcomes, MaxCyte is poised to capitalize on significant market opportunities in the life sciences sector.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$32.29M
Gross Profit (TTM)$25.99M
EBITDA$-34.16M
Operating Margin-64.10%
Return on Equity-21.30%
Return on Assets-11.30%
Revenue/Share (TTM)$0.30
Book Value$1.57
Price-to-Book0.65
Price-to-Sales (TTM)3.48
EV/Revenue0.616
EV/EBITDA-11.07
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-7.10%
Shares Outstanding$107.12M
Float$97.63M
% Insiders1.59%
% Institutions68.74%

Historical Volatility

HV 10-Day
71.11%
HV 20-Day
65.06%
HV 30-Day
62.58%
HV 60-Day
74.67%
HV Rank
39.7%

Volatility is currently expanding

Analyst Ratings

Consensus ($4.11 target)
5
Buy
2
Hold

Latest News

MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

ROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs.

GlobeNewsWire7/21/2026Neutral
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

ROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2026 after the U.S. market close on Wednesday, August 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

GlobeNewsWire7/15/2026Neutral
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million MaxCyte's Board authorized a $10 million share repurchase program ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results and reiterated its 2026 guidance.

GlobeNewsWire5/12/2026Neutral
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

GlobeNewsWire4/29/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MXCT and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/29/2026